Advanced Glycation Endproducts (AGEs) and Chronic Complications in Diabetes

[1]  G. Striker,et al.  Uremic Toxicity of Advanced Glycation End Products in CKD. , 2016, Journal of the American Society of Nephrology : JASN.

[2]  M. Woodward,et al.  Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[3]  J. Schmeidler,et al.  Dietary advanced glycation end products are associated with decline in memory in young elderly , 2014, Mechanisms of Ageing and Development.

[4]  Mark Woodward,et al.  Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans , 2014, Proceedings of the National Academy of Sciences.

[5]  G. Striker,et al.  Advanced glycation endproducts in diabetes and diabetic complications. , 2013, Endocrinology and metabolism clinics of North America.

[6]  L. Lipscombe,et al.  Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study , 2013, Diabetologia.

[7]  Michael E. Miller,et al.  Early Progression of Diabetic Nephropathy Correlates With Methylglyoxal-Derived Advanced Glycation End Products , 2013, Diabetes Care.

[8]  P. Oettgen,et al.  TGF-β Induces Acetylation of Chromatin and of Ets-1 to Alleviate Repression of miR-192 in Diabetic Nephropathy , 2013, Science Signaling.

[9]  Fredrik H. Karlsson,et al.  Gut metagenome in European women with normal, impaired and diabetic glucose control , 2013, Nature.

[10]  R. D'Agostino,et al.  Circulating Estrone Levels Are Associated Prospectively With Diabetes Risk in Men of the Framingham Heart Study , 2013, Diabetes Care.

[11]  B. Linder,et al.  The TODAY Study: An NIH Perspective on Its Implications for Research , 2013, Diabetes Care.

[12]  Lucie Geurts,et al.  Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity , 2013, Proceedings of the National Academy of Sciences.

[13]  B. Astor,et al.  Combined association of creatinine, albuminuria, and cystatin C with all-cause mortality and cardiovascular and kidney outcomes. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[14]  H. Sørensen,et al.  Type 2 diabetes and 1‐year mortality in intensive care unit patients , 2013, European journal of clinical investigation.

[15]  K. Nin,et al.  Circulating TNF receptor 2 is associated with the development of chronic kidney disease in non-obese Japanese patients with type 2 diabetes. , 2013, Diabetes research and clinical practice.

[16]  C. Büchel,et al.  Estrogen and the male hippocampus: Genetic variation in the aromatase gene predicting serum estrogen is associated with hippocampal gray matter volume in men , 2013, Hippocampus.

[17]  Sterling C. Johnson,et al.  Insulin Resistance, Brain Atrophy, and Cognitive Performance in Late Middle–Aged Adults , 2013, Diabetes Care.

[18]  M. Woodward,et al.  Managing chronic inflammation in the aging diabetic patient with CKD by diet or sevelamer carbonate: a modern paradigm shift. , 2012, The journals of gerontology. Series A, Biological sciences and medical sciences.

[19]  K. Tsuneyama,et al.  Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models. , 2012, The Journal of toxicological sciences.

[20]  G. Striker,et al.  Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1 , 2012, Proceedings of the National Academy of Sciences.

[21]  M. Woodward,et al.  Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[22]  T. Mayadas,et al.  Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. , 2012, Journal of the American Society of Nephrology : JASN.

[23]  G. Striker,et al.  Pentosan polysulfate inhibits atherosclerosis in Watanabe heritable hyperlipidemic rabbits: differential modulation of metalloproteinase-2 and -9 , 2012, Laboratory Investigation.

[24]  Dong Ho Jung,et al.  Increased glyoxalase I levels inhibit accumulation of oxidative stress and an advanced glycation end product in mouse mesangial cells cultured in high glucose. , 2012, Experimental cell research.

[25]  P. Schwingel,et al.  Hormone replacement therapy in menopausal women: risk factor or protection to nonalcoholic fatty liver disease? , 2012, Annals of hepatology.

[26]  Pierre J Magistretti,et al.  Role of the Glyoxalase System in Astrocyte-Mediated Neuroprotection , 2011, The Journal of Neuroscience.

[27]  M. Sano,et al.  Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals , 2011, Mechanisms of Ageing and Development.

[28]  H. Snieder,et al.  Glycotoxin and Autoantibodies Are Additive Environmentally Determined Predictors of Type 1 Diabetes , 2011, Diabetes.

[29]  G. Striker,et al.  Inhibition of inflammation by pentosan polysulfate impedes the development and progression of severe diabetic nephropathy in aging C57B6 mice , 2011, Laboratory Investigation.

[30]  G. Striker,et al.  Restriction of Advanced Glycation End Products Improves Insulin Resistance in Human Type 2 Diabetes , 2011, Diabetes Care.

[31]  G. Striker,et al.  AGE restriction in diabetes mellitus: a paradigm shift , 2011, Nature Reviews Endocrinology.

[32]  G. Striker,et al.  Maternally Transmitted and Food-Derived Glycotoxins , 2010, Diabetes Care.

[33]  G. Striker,et al.  AGER1 regulates endothelial cell NADPH oxidase-dependent oxidant stress via PKC-delta: implications for vascular disease. , 2010, American journal of physiology. Cell physiology.

[34]  C. Glass,et al.  Macrophages, inflammation, and insulin resistance. , 2010, Annual review of physiology.

[35]  L. Ferrucci,et al.  Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. , 2009, The Journal of clinical endocrinology and metabolism.

[36]  G. Striker,et al.  Advanced glycation end product receptor-1 transgenic mice are resistant to inflammation, oxidative stress, and post-injury intimal hyperplasia. , 2009, The American journal of pathology.

[37]  Daisuke Koya,et al.  SIRT1 and insulin resistance , 2009, Nature Reviews Endocrinology.

[38]  H. Vlassara,et al.  Advanced glycation end products inhibit glucose-stimulated insulin secretion through nitric oxide-dependent inhibition of cytochrome c oxidase and adenosine triphosphate synthesis. , 2009, Endocrinology.

[39]  S. Ye,et al.  Advanced Glycation End-Product of Low Density Lipoprotein Activates the Toll-Like 4 Receptor Pathway Implications for Diabetic Atherosclerosis , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[40]  G. Striker,et al.  Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. , 2008, The American journal of pathology.

[41]  B. Hudson,et al.  Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine. , 2008, Biochemistry.

[42]  G. Striker,et al.  Glycotoxins in the diet promote diabetes and diabetic complications , 2007, Current diabetes reports.

[43]  M. Trevisan,et al.  Elevated Cystatin C Concentration and Progression to Pre-Diabetes , 2007, Diabetes Care.

[44]  G. Striker,et al.  Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression. , 2007, The American journal of pathology.

[45]  Paul J Thornalley,et al.  Advanced glycation endproducts: what is their relevance to diabetic complications? , 2007, Diabetes, obesity & metabolism.

[46]  Bernd Stratmann,et al.  Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. , 2007, The American journal of clinical nutrition.

[47]  J. Uribarri,et al.  Prevention and Reversal of Diabetic Nephropathy in db/db Mice Treated with Alagebrium (ALT-711) , 2006, American Journal of Nephrology.

[48]  J. Flier,et al.  TLR4 links innate immunity and fatty acid-induced insulin resistance. , 2006, The Journal of clinical investigation.

[49]  J. He,et al.  Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor , 2006, Proceedings of the National Academy of Sciences.

[50]  P. Finot.  The absorption and metabolism of modified amino acids in processed foods. , 2005, Journal of AOAC International.

[51]  J. Uribarri,et al.  High Levels of Dietary Advanced Glycation End Products Transform Low-Dersity Lipoprotein Into a Potent Redox-Sensitive Mitogen-Activated Protein Kinase Stimulant in Diabetic Patients , 2004, Circulation.

[52]  K. Mcleish,et al.  Methylglyoxal: a stimulus to neutrophil oxygen radical production in chronic renal failure? , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[53]  J. Uribarri,et al.  Glycoxidation and inflammation in renal failure patients. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[54]  Paul J Thornalley.  Glyoxalase I--structure, function and a critical role in the enzymatic defence against glycation. , 2003, Biochemical Society transactions.

[55]  Guangtao Li,et al.  A specific segment of the transmembrane domain of Wbp1p is essential for its incorporation into the oligosaccharyl transferase complex. , 2003, Biochemistry.

[56]  K. Feingold,et al.  Oxidized cholesterol in the diet is a source of oxidized lipoproteins in human serum Published, JLR Papers in Press, February 1, 2003. DOI 10.1194/jlr.M200266-JLR200 , 2003, Journal of Lipid Research.

[57]  J. Uribarri,et al.  Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. , 2003, Journal of the American Society of Nephrology : JASN.

[58]  M. Peppa,et al.  Erratum: Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy (Proceedings of the National Academy of Sciences of the United States (November 26, 2002) 99:24 (15596-15601)) , 2003 .

[59]  E. Gale.  The rise of childhood type 1 diabetes in the 20th century. , 2002, Diabetes.

[60]  M. Peppa,et al.  Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[61]  M. Steffes,et al.  Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products , 2002, Diabetes/metabolism research and reviews.

[62]  M. Brownlee.  Biochemistry and molecular cell biology of diabetic complications , 2001, Nature.

[63]  H. Vlassara.  The AGE‐receptor in the pathogenesis of diabetic complications , 2001, Diabetes/metabolism research and reviews.

[64]  A. Schmidt,et al.  The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. , 2001, The Journal of clinical investigation.

[65]  A. Schmidt,et al.  Receptor for age (RAGE) is a gene within the major histocompatibility class III region: implications for host response mechanisms in homeostasis and chronic disease. , 2001, Frontiers in bioscience : a journal and virtual library.

[66]  N. Harada,et al.  Brain aromatase is neuroprotective. , 2001, Journal of neurobiology.

[67]  W. Jongen,et al.  Mutagenicity of heated sugar-casein systems: effect of the Maillard reaction. , 2000, Journal of agricultural and food chemistry.

[68]  G. Striker,et al.  Pentosan polysulfate treatment reduces cyclosporine-induced nephropathy in salt-depleted rats. , 1999, Transplantation.

[69]  G. Striker,et al.  Nephrotoxin exposure in utero reduces glomerular number in sclerosis-prone but not sclerosis-resistant mice. , 1999, Kidney international.

[70]  H. Vlassara,et al.  Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. , 1999, Diabetes.

[71]  S. Genuth,et al.  Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Contro , 1999, Diabetes.

[72]  R. Bucala,et al.  Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[73]  T. Lyons,et al.  The Advanced Glycation End Product, N-(Carboxymethyl)lysine, Is a Product of both Lipid Peroxidation and Glycoxidation Reactions (*) , 1996, The Journal of Biological Chemistry.

[74]  Yong Ming Li,et al.  Identification of Galectin-3 As a High-Affinity Binding Protein for Advanced Glycation End Products (AGE): A New Member of the AGE-Receptor Complex , 1995, Molecular medicine.

[75]  K. Tracey,et al.  Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[76]  Yong Ming Li,et al.  Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[77]  K. Kuwabara,et al.  Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[78]  E. Friedman,et al.  Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure , 1994, The Lancet.

[79]  R. Bucala,et al.  Lipid advanced glycosylation: pathway for lipid oxidation in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[80]  E. Friedman,et al.  Advanced glycosylation end products in patients with diabetic nephropathy. , 1991, The New England journal of medicine.

[81]  A. Cerami,et al.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.

[82]  A. Cerami,et al.  High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[83]  A. Cerami,et al.  Accumulation of diabetic rat peripheral nerve myelin by macrophages increases with the presence of advanced glycosylation endproducts , 1984, The Journal of experimental medicine.

[84]  A. Cerami,et al.  Excessive Nonenzymatic Glycosylation of Peripheral and Central Nervous System Myelin Components in Diabetic Rats , 1983, Diabetes.

[85]  A. Cerami,et al.  An ultrastructural study of chronic sodium cyanate-indiuced neuropathy. , 1977, Journal of neuropathology and experimental neurology.

[86]  G. Striker,et al.  Cardiovascular , Pulmonary and Renal Pathology Induction of Diabetes in Aged C 57 B 6 Mice Results in Severe Nephropathy An Association with Oxidative Stress , Endoplasmic Reticulum Stress , and Inflammation , 2010 .

[87]  J. Baynes,et al.  Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. , 1999, Diabetes.

[88]  S. Klahr,et al.  Clinical trials in progression of chronic renal failure. , 1997, Advances in internal medicine.

[89]  G. Striker,et al.  Administration of AGEs in vivo induces extracellular matrix gene expression. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[90]  H. Vlassara.  Advanced glycosylation in nephropathy of diabetes and aging. , 1996, Advances in nephrology from the Necker Hospital.